Armin Zittermann1, Jana B Ernst2, Sylvana Prokop2, Uwe Fuchs2, Jens Dreier3, Joachim Kuhn3, Cornelius Knabbe3, Heiner K Berthold4, Ioanna Gouni-Berthold5, Jan F Gummert2, Jochen Börgermann2, Stefan Pilz6. 1. Clinic for Thoracic and Cardiovascular Surgery, Herz- und Diabeteszentrum NRW, Georgstraße 11, 32545, Bad Oeynhausen, Germany. azittermann@hdz-nrw.de. 2. Clinic for Thoracic and Cardiovascular Surgery, Herz- und Diabeteszentrum NRW, Georgstraße 11, 32545, Bad Oeynhausen, Germany. 3. Institute for Laboratory and Transfusion Medicine, Herz- und Diabeteszentrum NRW, Ruhr University Bochum, Bad Oeynhausen, Germany. 4. Department of Internal Medicine and Geriatrics, Bethel Clinic (EvKB), Bielefeld, Germany. 5. Polyclinic for Endocrinology, Diabetes and Preventive Medicine (PEDP), University of Cologne, Cologne, Germany. 6. Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Abstract
PURPOSE: Observational studies indicate a positive association between circulating 25-hydroxyvitamin D (25OHD) and testosterone (T) concentrations. Because low 25OHD concentrations and T deficiency are considered to be a generalized phenomenon in patients with advanced heart failure (HF), we aimed to investigate whether vitamin D supplementation has beneficial effects on T indices in these patients. METHODS: In a pre-specified secondary analysis of the EVITA (effect of vitamin D on mortality in heart failure) randomized controlled trial, we analyzed in male subjects with 25OHD concentrations < 75 nmol/L the effect of a daily vitamin D3 supplement of 4000 IU for 3 years (n = 71) vs. placebo (n = 62) on total T (TT), sex hormone-binding globulin (SHBG), free T (fT), and bioactive T (BAT). We assessed changes from baseline until study termination and between-group differences at study termination. RESULTS:25OHD increased in the placebo group from 36.6 nmol/L by 9.2 nmol/L (95% CI 3.2-15.1 nmol/L; P = 0.003) and in the vitamin D group from 36.5 nmol/L by 63.9 nmol/L (95% CI 52.6-75.3 nmol/L; P < 0.001), with a significant between-group difference at study termination (P < 0.001). TT and SHBG concentrations did not change significantly, neither in the placebo group nor in the vitamin D group (P = 0.845-0.082), but concentrations of fT and BAT declined significantly in both groups (P = 0.025-0.008). At study termination, there were no between-group differences in TT (P = 0.612), SHBG (P = 0.393), fT (P = 0.861), or BAT (P = 0.960). CONCLUSIONS: In male patients with advanced HF and low 25OHD concentrations, a daily vitamin D3 supplement of 4000 IU for 3 years did not prevent the decline in testosterone indices.
RCT Entities:
PURPOSE: Observational studies indicate a positive association between circulating 25-hydroxyvitamin D (25OHD) and testosterone (T) concentrations. Because low 25OHD concentrations and T deficiency are considered to be a generalized phenomenon in patients with advanced heart failure (HF), we aimed to investigate whether vitamin D supplementation has beneficial effects on T indices in these patients. METHODS: In a pre-specified secondary analysis of the EVITA (effect of vitamin D on mortality in heart failure) randomized controlled trial, we analyzed in male subjects with 25OHD concentrations < 75 nmol/L the effect of a daily vitamin D3 supplement of 4000 IU for 3 years (n = 71) vs. placebo (n = 62) on total T (TT), sex hormone-binding globulin (SHBG), free T (fT), and bioactive T (BAT). We assessed changes from baseline until study termination and between-group differences at study termination. RESULTS: 25OHD increased in the placebo group from 36.6 nmol/L by 9.2 nmol/L (95% CI 3.2-15.1 nmol/L; P = 0.003) and in the vitamin D group from 36.5 nmol/L by 63.9 nmol/L (95% CI 52.6-75.3 nmol/L; P < 0.001), with a significant between-group difference at study termination (P < 0.001). TT and SHBG concentrations did not change significantly, neither in the placebo group nor in the vitamin D group (P = 0.845-0.082), but concentrations of fT and BAT declined significantly in both groups (P = 0.025-0.008). At study termination, there were no between-group differences in TT (P = 0.612), SHBG (P = 0.393), fT (P = 0.861), or BAT (P = 0.960). CONCLUSIONS: In male patients with advanced HF and low 25OHD concentrations, a daily vitamin D3 supplement of 4000 IU for 3 years did not prevent the decline in testosterone indices.
Entities:
Keywords:
Bioactive testosterone; Free testosterone; Heart failure; Randomized controlled trial; Sex hormone; Testosterone; Vitamin D
Authors: David M Lee; Abdelouahid Tajar; Stephen R Pye; Steven Boonen; Dirk Vanderschueren; Roger Bouillon; Terence W O'Neill; Gyorgy Bartfai; Felipe F Casanueva; Joseph D Finn; Gianni Forti; Aleksander Giwercman; Thang S Han; Ilpo T Huhtaniemi; Krzysztof Kula; Michael E J Lean; Neil Pendleton; Margus Punab; Frederick C W Wu Journal: Eur J Endocrinol Date: 2011-11-02 Impact factor: 6.664
Authors: S Pilz; S Frisch; H Koertke; J Kuhn; J Dreier; B Obermayer-Pietsch; E Wehr; A Zittermann Journal: Horm Metab Res Date: 2010-12-10 Impact factor: 2.936
Authors: R Rafiq; N M van Schoor; E Sohl; M C Zillikens; M M Oosterwerff; L Schaap; P Lips; R T de Jongh Journal: J Steroid Biochem Mol Biol Date: 2015-11-21 Impact factor: 4.292
Authors: Armin Zittermann; Jana B Ernst; Sylvana Prokop; Uwe Fuchs; Jens Dreier; Joachim Kuhn; Cornelius Knabbe; Ingvild Birschmann; Uwe Schulz; Heiner K Berthold; Stefan Pilz; Ioanna Gouni-Berthold; Jan F Gummert; Marcus Dittrich; Jochen Börgermann Journal: Eur Heart J Date: 2017-08-01 Impact factor: 29.983
Authors: Ryan Janjuha; Diane Bunn; Richard Hayhoe; Lee Hooper; Asmaa Abdelhamid; Shaan Mahmood; Joseph Hayden-Case; Will Appleyard; Sophie Morris; Ailsa Welch Journal: Nutrients Date: 2020-05-18 Impact factor: 5.717
Authors: Luke A Robles; Sean Harrison; Vanessa Y Tan; Rhona Beynon; Alexandra McAleenan; Julian Pt Higgins; Richard M Martin; Sarah J Lewis Journal: Cancer Causes Control Date: 2022-06-26 Impact factor: 2.532
Authors: Armin Zittermann; Jana B Ernst; Sylvana Prokop; Uwe Fuchs; Jens Dreier; Joachim Kuhn; Cornelius Knabbe; Jochen Börgermann; Heiner K Berthold; Stefan Pilz; Ioanna Gouni-Berthold; Jan F Gummert Journal: Int J Endocrinol Date: 2018-07-03 Impact factor: 3.257